Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Pedro Calves"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
The NEAT Predictive Model for Survival in Patients with Advanced Cancer
Amanda Zucker, Chiaojung Jillian Tsai, John Loscalzo, Pedro Calves, Johnny Kao
Cancer Res Treat. 2018;50(4):1433-1443.   Published online January 24, 2018
DOI: https://doi.org/10.4143/crt.2017.223
AbstractAbstract PDFPubReaderePub
Purpose
We previously developed a model to more accurately predict life expectancy for stage IV cancer patients referred to radiation oncology. The goals of this study are to validate this model and to compare competing published models.
Materials and Methods
From May 2012 to March 2015, 280 consecutive patientswith stage IV cancerwere prospectively evaluated by a single radiation oncologist. Patients were separated into training, validation and combined sets. TheNEAT model evaluated number of active tumors (“N”), Eastern Cooperative Oncology Group performance status (“E”), albumin (“A”) and primary tumor site (“T”). The Odette Cancer Center model validated performance status, bone only metastases and primary tumor site. The Harvard TEACHH model investigated primary tumor type, performance status, age, prior chemotherapy courses, liver metastases, and hospitalization within 3 months. Cox multivariable analyses and logisticalregressionwere utilized to compare model performance.
Results
Number of active tumors, performance status, albumin, primary tumor site, prior hospitalizationwithin the last 3 months, and liver metastases predicted overall survival on uinvariate and multivariable analysis (p < 0.05 for all). The NEAT model separated patients into four prognostic groups with median survivals of 24.9, 14.8, 4.0, and 1.2 months, respectively (p < 0.001). The NEAT model had a C-index of 0.76 with a Nagelkerke’s R2 of 0.54 suggesting good discrimination, calibration and total performance compared to competing prognostic models.
Conclusion
The NEAT model warrants further investigation as a clinically useful approach to predict survival in patients with stage IV cancer.

Citations

Citations to this article as recorded by  
  • Nutritional care pathways in cancer patients with malignant bowel obstruction: A retrospective multi-centre study
    Pinal S. Patel, Konstantinos Fragkos, Niamh Keane, David Wilkinson, Amy Johnson, Derek Chan, Bradley Roberts, Penny Neild, Metin Yalcin, Philip Allan, Michael E.B. FitzPatrick, Michael Gomez, Sarah Williams, Klaartje Kok, Lisa Sharkey, Carla Swift, Shamee
    Clinical Nutrition ESPEN.2024; 59: 118.     CrossRef
  • Predicting long‑term survival following involved site radiotherapy for oligometastases
    Johnny Kao, Patricia Eckardt, Jennifer Mceachron, Christopher Atalla, Ashish Sangal
    Oncology Letters.2024;[Epub]     CrossRef
  • Palliative radiotherapy: survival prognostic factors - single-centre retrospective cohort study
    Sian Cooper, Mary Denholm, Abdul Shawal Malek, Jeffrey Arun Rubasingham, David Tsang
    BMJ Supportive & Palliative Care.2024; : spcare-2024-004810.     CrossRef
  • Thirty‐day mortality after palliative radiotherapy in advanced cancer patients: Optimizing end‐of‐life care in Asia
    Mi Sun Kim, Hyejung Cha, Sei Hwan You, Sunghyun Kim
    Journal of Medical Imaging and Radiation Oncology.2024; 68(3): 307.     CrossRef
  • Palliative Appropriateness Criteria: A Pragmatic Method to Evaluate the Suitability of Palliative Radiotherapy Fractionation
    Joshua C. Farris, Adam G. Johnson, Patrick P. Carriere, Zachary A. Patel, Moeko Nagatsuka, Michael K. Farris, Ryan T. Hughes
    Journal of Palliative Medicine.2023; 26(1): 67.     CrossRef
  • The LabPS score
    Carsten Nieder, Ellinor C. Haukland, Bård Mannsåker, Astrid Dalhaug
    American Journal of Clinical Oncology.2023; 46(4): 178.     CrossRef
  • Long-term disease-free survival following comprehensive involved site radiotherapy for oligometastases
    Johnny Kao, Michelle Sahagian, Vani Gupta, Symeon Missios, Ashish Sangal
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis
    Justin Henry Kutzko, Parvati Dadwal, Tanya Holt, Muhammed Aashiq Rahman, Syeda Farah Zahir, Brigid Hickey
    Radiotherapy and Oncology.2022; 168: 147.     CrossRef
  • Risk Stratification for Imminent Risk of Death at the Time of Palliative Radiotherapy Consultation
    Susan Y. Wu, Emily Yee, Harish N. Vasudevan, Shannon E. Fogh, Lauren Boreta, Steve E. Braunstein, Julian C. Hong
    JAMA Network Open.2021; 4(7): e2115641.     CrossRef
  • Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review
    André G. Gouveia, Dominic C.W. Chan, Peter J. Hoskin, Gustavo N. Marta, Fabio Trippa, Ernesto Maranzano, Edward Chow, Mauricio F. Silva
    Radiotherapy and Oncology.2021; 163: 55.     CrossRef
  • Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care
    Matthew S. Ning, Prajnan Das, David I. Rosenthal, Bouthaina S. Dabaja, Zhongxing Liao, Joe Y. Chang, Daniel R. Gomez, Ann H. Klopp, G. Brandon Gunn, Pamela K. Allen, Paige L. Nitsch, Rachel B. Natter, Tina M. Briere, Joseph M. Herman, Rebecca Wells, Alber
    Journal of the National Comprehensive Cancer Network.2021; 19(7): 805.     CrossRef
  • Association of radiation dose intensity with overall survival in patients with distant metastases
    Johnny Kao, Mark K. Farrugia, Samantha Frontario, Amanda Zucker, Emily Copel, John Loscalzo, Ashish Sangal, Boramir Darakchiev, Anurag Singh, Symeon Missios
    Cancer Medicine.2021; 10(22): 7934.     CrossRef
  • Palliative Radiotherapy
    William Tristram Arscott, Jaclyn Emmett, Alireza Fotouhi Ghiam, Joshua A. Jones
    Hematology/Oncology Clinics of North America.2020; 34(1): 253.     CrossRef
  • Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network
    Adrianna E. Mojica-Márquez, Joshua L. Rodríguez-López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan, Sushil Beriwal
    Journal of Pain and Symptom Management.2020; 60(5): 898.     CrossRef
  • External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end‐of‐life
    Adrianna E. Mojica‐Márquez, Joshua L. Rodríguez‐López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan, Sushil Beriwal
    Cancer Medicine.2020; 9(16): 5781.     CrossRef
  • Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018
    Erin F. Gillespie, Kaitlyn Lapen, Diana G. Wang, N. Wijetunga, Gerri L. Pastrana, Marisa A. Kollmeier, Josh Yamada, Adam M. Schmitt, Daniel S. Higginson, Max Vaynrub, Ernesto Santos Martin, Amy J. Xu, C. Jillian Tsai, Divya Yerramilli, Oren Cahlon, T. Jon
    Clinical and Translational Radiation Oncology.2020; 25: 75.     CrossRef
  • Palliative radiotherapy near the end of life
    Susan Y. Wu, Lisa Singer, Lauren Boreta, Michael A. Garcia, Shannon E. Fogh, Steve E. Braunstein
    BMC Palliative Care.2019;[Epub]     CrossRef
  • Blood Albumin As A Prognostic Factor Among Unselected Medically Treated Inpatients
    Krzysztof Tojek, Gabriel Kowalczyk, Beata Czerniak, Wioletta Banaś, Beata Szukay, Wanda Korzycka-Wilińska, Zbigniew Banaszkiewicz, Jacek Budzyński
    Biomarkers in Medicine.2019; 13(13): 1059.     CrossRef
  • 8,244 View
  • 181 Download
  • 23 Web of Science
  • 18 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP